Excelsior Biopharma Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 300.65 million compared to TWD 367.98 million a year ago. Net loss was TWD 12.55 million compared to net income of TWD 8.31 million a year ago. Basic loss per share from continuing operations was TWD 0.27 compared to basic earnings per share from continuing operations of TWD 0.18 a year ago. Diluted loss per share from continuing operations was TWD 0.27 compared to diluted earnings per share from continuing operations of TWD 0.18 a year ago. For the nine months, sales was TWD 971.34 million compared to TWD 1,099.96 million a year ago. Net loss was TWD 12.89 million compared to net income of TWD 31.67 million a year ago. Basic loss per share from continuing operations was TWD 0.28 compared to basic earnings per share from continuing operations of TWD 0.68 a year ago. Diluted loss per share from continuing operations was TWD 0.28 compared to diluted earnings per share from continuing operations of TWD 0.67 a year ago.